RIPK1-IN-32
RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.
For research use only. We do not sell to patients.
- Formula: C42H59NO7S2
- Molecular Weight:754.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
IL-6 |
RIPK1 |
In Vitro
RIPK1-IN-32 (Compound 12) (0-25 μM, 45-63 °C) significantly inhibits the thermal degradation of RIPK1 in RAW264.7 macrophages[1].
RIPK1-IN-32 (2.5 μM) significantly diminishes p65 and c-fos nuclear translocation in RAW264.7 macrophages[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) notably reduces d the levels of IL-6 and TNF-α in RAW 264.7 cells[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) effectively hinders the LPS (HY-D1056B3)-induced activation of the RIPK1/NF-κB/MAPK pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated RAW 264.7 macrophages
-
Concentration:0.625, 1.25, 2.5 μM
-
Incubation Time:8 h, including 1 μg/mL LPS for 6 hours
-
Result:Significantly diminished the contents of IL-6 and TNF-α.
-
Cell Line:LPS-stimulated RAW 264.7 macrophages
-
Concentration:0.625, 1.25, 2.5 μM
-
Incubation Time:8 h, including 1 μg/mL LPS for 6 hours
-
Result:Resulted in notable decreases in the levels of RIPK1, p-p65, and p-IκB suggesting an inhibition of NF-κB signaling.
Found to lower the protein levels of p-p38, p-ERK, and p-JNK which aligns with the suppression of MAPK signaling.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS injection into the tail vein to create a sepsis model established in Male BALB/c mice (18-20 g)[1]
-
Dosage:1.25, 2.5 and 5 mg/kg
-
Administration:Intravenous injection (i.v.), single dose
-
Result:Markedly alleviated LPS-induced ALI.
Decreased the serum levels of ALT and AST.
Significantly diminished the contents of IL-6 and TNF-α.
Attenuated the damage to lung tissue and markedly lessened the pathological alterations noted in the kidneys subsequent.
Decreased in liver concentrations of RIPK1, p-p65, P-IκB, p-p38, p-ERK, and p-JNK.
Chemical Information
-
Molecular Weight 754.05
-
Formula C42H59NO7S2
-
SMILES
[H][C@@]12CC[C@@]([C@]3(C)[C@@](C4=C(C(O[C@H]4C3)=O)CC/C=C(C)/C)([H])C[C@H]5O)(C)[C@@]5([C@]1(CC[C@H]([C@H]2C)OC(CCSSCCC(NOCC6=CC=CC=C6)=O)=O)C)[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)